Fallah, M.

screening cancer lead-time prostate prostate cancer control arm detection incidence control detection rate round study prostate cancer screening fi rst round 4 ng /ml finland european overdiagnosi belgium netherland interval european randomised study trial prostate cancer incidence disease centre italy 3 ng /ml estimate ratio serum screen-detected sweden prevalence population country screening interval control group screening round cancer 4 6 follow-up fi ve centres number group colorectal cancer screening diagnosis randomised screening arm serum psa table screening test journal antigen 8 years erspc result sensitivity biopsy model analysis serum bank studies distribution cancer cases european journal approach 4–8 years european randomized study dutch screening trial incidence rates fi ve countries follow-up time level absence history randomized stage contamination screen health state